Not Yet Recruiting PHASE4 INTERVENTIONAL 3-arm NCT06448130

Henagliflozin's Impact on Prediabetes Remission

Effect of Henagliflozin on the Remission of Prediabetes Population: A National Multicenter, Randomized Controlled Study

Sponsor: Shandong Provincial Hospital

Conditions Glucose Metabolism Disorders PreDiabetes Prediabetic State Type 2 Diabetes

Interventions Henagliflozin 10mg Henagliflozin 5mg Placebo

Updated 3 times since 2024 Last updated: Jun 3, 2024 Started: Jun 30, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06448130, this PHASE4 trial focuses on Glucose Metabolism Disorders and PreDiabetes and remains actively recruiting participants. Sponsored by Shandong Provincial Hospital, it has been updated 3 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE4
Sep 2024 — Sep 2025 [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong Provincial Hospital

Data source: Shandong Provincial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baotou, China , Beijing, China , Binzhou, China , Changchun, China , Changsha, China , Chongqing, China , Chuzhou, China , Dongying, China , Foshan, China , Fuzhou, China and 29 more locations